850409-29-9

Upstream product

• 850307-81-2 (2S)-5,7-bis(benzyloxy)-8-benzyl-2-[3,4-bis(benzyloxy)phenyl]chroman-3-one 
• 850307-78-7 2-benzyl-3,5-bis(benzyloxy)phenol 
• 850307-79-8 (E)-3-[2,4-bis(benzyloxy)-5-benzyl-6-hydroxyphenyl]-1-[3,4-bis(benzyloxy)phenyl]propene 
• 850409-28-8 (2S,3R)-trans-5,7-bis(benzyloxy)-8-benzyl-2-[3,4-bis(benzyloxy)phenyl]chroman-3-ol 
• 850307-80-1 (1R,2R)-3-[2,4-bis(benzyloxy)-5-benzyl-6-hydroxyphenyl]-1-[3,4-bis(benzyloxy)phenyl]propane-1,2-diol 
• 59434-20-7 1,3,5-tri-O-benzylphloroglucinol 

Downstream Products

• 850307-82-3 (2S,3S)-cis-5,7-bis(benzyloxy)-8-benzyl-2-[3,4-bis(benzyloxy)phenyl]chroman-3-yl 3,4,5-tris(benzyloxy)benzoate 

Relevant academic research and scientific papers

Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors

The structure-activity relationship of a number of synthetic green tea polyphenol analogs involving modifications of A ring and B ring of epi-gallocatechin gallate (EGCG) as proteasome inhibitors has been examined. It was found that in B ring, a decrease in the number of OH groups led to decreased potency. Introduction of a hydrophobic benzyl group into the 8 position of A ring did not significantly affect the proteasome-inhibitory potency.